CSW (NASDAQ:CSWI) Reports Sales Below Analyst Estimates In Q1 Earnings
Industrial products company CSW (NASDAQ:CSWI) fell short of the market's revenue expectations in Q1 CY2025, but sales rose 9.3% year on year to $230.5 million. Its non-GAAP profit of $2.24 per share was 1.1% above analysts' consensus estimates.
Is now the time to buy CSW? Find out in our full research report.
Revenue: $230.5 million vs analyst estimates of $232.8 million (9.3% year-on-year growth, 1% miss)
Adjusted EPS: $2.24 vs analyst estimates of $2.22 (1.1% beat)
Adjusted EBITDA: $59.76 million vs analyst estimates of $60.37 million (25.9% margin, 1% miss)
Operating Margin: 19.5%, down from 22% in the same quarter last year
Free Cash Flow Margin: 9.9%, up from 8.3% in the same quarter last year
Market Capitalization: $5.28 billion
"Total revenue increased 10.8% to $878.3 million, of which $47.5 million, or 6.0%, was inorganic growth from recent acquisitions, and 4.8%, or $37.9 million was organic growth. Contractor Solutions delivered organic revenue growth of 6.2% during the fiscal full year. Net income attributable to CSWI of $136.7 million, or $137.2 million adjusted, increased 25.7% as compared to $109.1 million. EPS of $8.38, or $8.41 adjusted, improved 20.0% compared to $7.01. Adjusted EBITDA increased 13.9% to $227.9 million, including margin expansion of 70 bps to 25.9%. Invested $84.7 million in acquisitions of PSP Products and PF Waterworks and $16.3 million in organic capital expenditures, while returning total cash of $32.9 million to shareholders through share repurchases of $18.3 million and dividends of $14.6 million. Subsequent to fiscal year-end, announced transfer of listing of common stock to the New York Stock Exchange beginning June 9, 2025, and change in ticker symbol to CSW" Comments from the Chairman, President, and Chief Executive Officer
With over two centuries of combined operations manufacturing and supplying, CSW (NASDAQ:CSWI) offers special chemicals, coatings, sealants, and lubricants for various industries.
A company's long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, CSW grew its sales at an incredible 17.9% compounded annual growth rate. Its growth surpassed the average industrials company and shows its offerings resonate with customers, a great starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. CSW's annualized revenue growth of 7.7% over the last two years is below its five-year trend, but we still think the results were respectable.
This quarter, CSW's revenue grew by 9.3% year on year to $230.5 million, missing Wall Street's estimates.
Looking ahead, sell-side analysts expect revenue to grow 12.6% over the next 12 months, an improvement versus the last two years. This projection is noteworthy and indicates its newer products and services will spur better top-line performance.
Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after procuring and manufacturing its products, marketing and selling those products, and most importantly, keeping them relevant through research and development.
CSW has been a well-oiled machine over the last five years. It demonstrated elite profitability for an industrials business, boasting an average operating margin of 18.7%. This result isn't surprising as its high gross margin gives it a favorable starting point.
Analyzing the trend in its profitability, CSW's operating margin rose by 3.9 percentage points over the last five years, as its sales growth gave it operating leverage.
In Q1, CSW generated an operating profit margin of 19.5%, down 2.5 percentage points year on year. Since CSW's operating margin decreased more than its gross margin, we can assume it was less efficient because expenses such as marketing, R&D, and administrative overhead increased.
Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
CSW's EPS grew at an astounding 24.5% compounded annual growth rate over the last five years, higher than its 17.9% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
We can take a deeper look into CSW's earnings to better understand the drivers of its performance. As we mentioned earlier, CSW's operating margin declined this quarter but expanded by 3.9 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals.
Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business.
For CSW, its two-year annual EPS growth of 17.6% was lower than its five-year trend. We still think its growth was good and hope it can accelerate in the future.
In Q1, CSW reported EPS at $2.24, up from $2.04 in the same quarter last year. This print beat analysts' estimates by 1.1%. Over the next 12 months, Wall Street expects CSW's full-year EPS of $8.57 to grow 11%.
Revenue missed slightly, but EPS beat slightly. Overall, we'd call this quarter fairly online, neither great nor terrible. The stock remained flat at $312.45 immediately following the results.
CSW's latest earnings report disappointed. One quarter doesn't define a company's quality, so let's explore whether the stock is a buy at the current price. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Inflation Cools, Jobs Steady--Is This the Market Rebound Investors Have Been Waiting For?
Consumer anxiety about rising prices may finally be easingand the timing could matter. According to fresh data from the New York Fed, Americans now see inflation coming in lower than they did just a month ago. Median year-ahead expectations dropped to 3.2% in May, down from 3.6% in April. Three- and five-year views also edged lower, now sitting at 3.0% and 2.6%, respectively. The shift follows a temporary de-escalation in trade tensions, with President Trump agreeing to reduce tariffs on Chinese imports. That announcement, while short-term, may have helped reverse the negative consumer sentiment that had been building since early this year. The job picture isn't boomingbut it might be stabilizing. Americans' perceived risk of losing their job over the next year ticked slightly lower, and more people say they feel confident enough to quit voluntarily. That's typically a positive signal for labor markets. At the same time, the share of households saying they expect to be financially worse off in a year has shrunk, and fewer respondents report difficulty accessing credit. Perhaps more telling: the average probability of missing a loan payment has dropped to its lowest point since Januaryhinting at some relief from financial stress, even as parts of the economy remain under pressure. This shift in sentiment may be influencing how people see the market. More consumers now expect the U.S. stock market to be higher a year from now. That optimism, combined with cooler inflation expectations and fewer job fears, could support short-term risk appetite heading into the summer. The Federal Reserve is widely expected to keep rates on pause at its upcoming June 1718 meeting, giving markets more room to digest the macro shifts. Tesla (NASDAQ:TSLA) and other high-beta names might see increased investor interest if this rebound in consumer confidence translates into steadier flows into equities. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
See the Incredible Returns If You Invested in 10 of the Top Performing Stocks Over the Last 5 Years (Including GameStop)
Volatility is no fun if you're a stock market investor — and there's been plenty of that so far in 2025. But it's important to keep in mind that stocks in general have always produced strong returns over time. The S&P 500 has risen by about 91% over the past five years alone, despite major headwinds ranging from COVID-19 and soaring inflation to President Donald Trump's current tariff threats. The Dow is up about 62% over the same time frame, while the Nasdaq has roughly doubled in value. Discover More: Find Out: Those are all very good returns, but they pale in comparison to the best performing stocks. If you were fortunate enough to invest in one of those, you would have seen your money rise more than 10-fold in the last half-decade. One reason some of the best performers rose so fast is that they traded at very low values five years ago — in some cases around $1 a share. Any spike in value would represent a major percentage gain. An example is GameStop, the gaming and entertainment company whose stock could be purchased for a little more than $1 a share in June 2020. GameStop grabbed headlines in early 2021 when professional investors shorted the stock, figuring it would go down in value. But as EBSCO noted at the time, a 'wave' of amateur investors started buying up shares and helped the stock soar by more than 1,500% in a matter of weeks. Today, GameStop trades for around $30 a share. If you had invested $100 in the company in early June of 2020, your investment would now be worth more than $2,500. Here's a look at the massive returns you would have gotten by investing in 10 of the top performing stocks over the past five years. Each has risen by at least 1,000% and boasts a current price of roughly $30 a share or more. Trending Now: Closing price June 8, 2020: $3.10 per share Closing price June 4, 2020: $132.41 5-year return: 4,171% Closing price June 8, 2020: $1.25 Closing price June 4, 2020: $44.97 5-year return: 3,498% Closing price June 8, 2020: $11.80 Closing price June 4, 2020: $378.10 5-year return: 3,104% Closing price June 8, 2020: $1.18 Closing price June 4, 2020: $29.95 5-year return: 2,438% Closing price June 8, 2020: $3.97 Closing price June 4, 2020: $84.89 5-year return: 2,038% Closing price June 8, 2020: $10.51 Closing price June 4, 2020: $193.81 5-year return: 1,744% Closing price June 8, 2020: $6.57 Closing price June 4, 2020: $119.90 5-year return: 1,725% Closing price June 8, 2020: $5.35 Closing price June 4, 2020: $91.66 5-year return: 1,613% Closing price June 8, 2020: $2.71 Closing price June 4, 2020: $46.16 5-year return: 1,603% Closing price June 8, 2020: $10.37 Closing price June 4, 2020: $122.82 5-year return: 1,084% More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 8 Common Mistakes Retirees Make With Their Social Security Checks 10 Cars That Outlast the Average Vehicle This article originally appeared on See the Incredible Returns If You Invested in 10 of the Top Performing Stocks Over the Last 5 Years (Including GameStop)
